By The Life Science Report
http://www.thelifesciencesreport.com/pub/na/17040
Oxycodone is a powerful and lucrative painkiller, but one with serious downsides. Dependency on the opioid has become a major issue medically, politically and, most profoundly, for the patients whose addictions have become debilitating or fatal. DURECT Corp.’s Remoxy, an abuse-deterrent formulation of oxycodone, has an FDA approval date of Sept. 25, 2016, and may provide a safer alternative.
Rodman and Renshaw analyst Raghuram Selvaraju, in a research report issued July 5, noted the FDA has decided not to hold an Advisory Committee (AdCom) meeting for DURECT Corp.’s (DRRX:NASDAQ) Remoxy, and to retain the Sept. 25 Prescription Drug User Fee Act (PDUFA) date.
“We believe this suggests that the efficacy and safety profile of Remoxy has been well presented in the NDA (new drug application) package, from the FDA’s perspective. . .therefore, in our view, Remoxy is likely to secure regulatory approval in September,” Selvaraju wrote.
Remoxy’s abuse-deterrent formulation is key to its potential approval, Selvaraju notes. “Remoxy’s thick, sticky, high-viscosity formulation may deter unapproved routes of drug administration, such as injection, snorting or smoking. Investors may know that oxycodone abuse and diversion remains a serious, persistent problem. Nearly 19,000 people died from opioid overdose in 2014, according to the National Institute on Drug Abuse.”
Free Reports:
Selvaraju believes that, given the deterrent formulation, Remoxy “should be able to seize a significant market share” from Purdue Pharma’s OxyContin, which the analyst notes earns $2 billion in revenues annually.
DURECT and collaborator Pain Therapeutics could expect to “generate peak sales of over $300M a year,” Selvaraju wrote. “DURECT is entitled to receive royalties for Remoxy ranging from 6.0% to 11.5% of net sales.”
Remoxy addresses other issues that have surfaced with OxyContin, according to the company’s chief financial officer, Matthew Hogan. Purdue Pharma’s drug is touted as a twice-daily pain reliever, but a Los Angeles Times exposé published in May revealed that, for many patients, the drug is effective for only eight hours. This, according to the Times, means patients may take more pills than prescribed, running the risk of overdose. The pharmacokinetics of DURECT’s Remoxy, Hogan noted, have been developed so that the drug’s effects are “metered out over the full 12 hours.”
DURECT’s Remoxy may also benefit from the stigma now associated with OxyContin. Doctors may find it preferable to prescribe a drug that is both tamper- and addiction-resistant, and patients may find it preferable to take a drug without a bad reputation, Hogan said.
Recognizing that dosage is also a factor in abuse and addiction, Remoxy is being formulated in five strengths, from 5 milligrams (5 mg) to 40 mg. The 5 mg dosage would be the lowest commercially available at the present time, which is consistent with recent government recommendations that patients on extended-release opioids should “start low and go slow” with their doses. “Remoxy is attempting to be a highly responsible citizen in serving the needs of legitimate chronic pain sufferers,” Hogan told The Life Sciences Report.
Though Remoxy is in the spotlight right now, DURECT’s pipeline also includes a “late-stage, post-surgical pain product Posimir in Phase 3, and a new chemical entity, DUR-928, an endogenous small molecule that has shown the potential for utility in a number of liver conditions as well as acute organ injury,” Hogan noted.
Read what other experts are saying about:
Want to read more Life Sciences Report interviews like this? Sign up for our free e-newsletter, and you’ll learn when new articles have been published. To see recent interviews with industry analysts and commentators, visit our Streetwise Interviews page.
Disclosures:
1) Tracy Salcedo compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She owns, or her family owns, shares of the following companies mentioned in this interview: None.
2) The following companies mentioned in the article are sponsors of Streetwise Reports: DURECT Corp. Streetwise Reports does not accept stock in exchange for its services. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
3) Matt Hogan, CFO of DURECT Corp., was not paid by Streetwise Reports for providing commentary in this article. Comments and opinions expressed are his own comments and opinions. He had the opportunity to review the article for accuracy and is responsible for his comments therein.
4) Raghuram Selvaraju: Neither I, nor any member of my family, own any shares of the following companies mentioned in this article: None. Neither I personally, nor any member of my family, are paid by the following companies mentioned in this article: None. My company does not own any shares of any companies mentioned in this article, nor has my company performed investment banking services for any of the companies mentioned in this article. I was not paid by Streetwise Reports for providing commentary in this article. Comments and opinions expressed are my own comments and opinions. I had the opportunity to review the article for accuracy and am responsible for my comments therein.
5) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports’ terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
6) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their families are prohibited from making purchases and/or sales of those securities in the open market or otherwise during the up-to-four-week interval from the time of the interview until after it publishes.
Streetwise – The Life Sciences Report is Copyright © 2016 by Streetwise Reports LLC. All rights are reserved. Streetwise Reports LLC hereby grants an unrestricted license to use or disseminate this copyrighted material (i) only in whole (and always including this disclaimer), but (ii) never in part.
Streetwise Reports LLC does not guarantee the accuracy or thoroughness of the information reported.
Streetwise Reports LLC receives a fee from companies that are listed on the home page in the In This Issue section. Their sponsor pages may be considered advertising for the purposes of 18 U.S.C. 1734.
Participating companies provide the logos used in The Life Sciences Report. These logos are trademarks and are the property of the individual companies.
101 Second St., Suite 110
Petaluma, CA 94952
Tel.: (707) 981-8999
Fax: (707) 773-5020
Email: info@streetwisereports.com